Navigation Links
Chem Rx Corporation Reports First Quarter 2008 Financial Results
Date:5/30/2008

- Conference Call Scheduled Tuesday, June 3, 2008 at 8:30 a.m. ET -

Recent Highlights: - First quarter 2008 net sales increased 20.2% year-over-year to $87.5

million - Net beds served increased 8.5% year-over-year to 65,700 at March 31, 2008

- First quarter 2008 gross profit rose 21.6% to $22.0 million

- Stock symbol changed to CHRX from PMQC

LONG BEACH, N.Y., May 30 /PRNewswire-FirstCall/ -- Chem Rx Corporation (OTC Bulletin Board: CHRX, CHRXU, CHRXW), a leading provider of institutional pharmacy services, today reported financial results for the first quarter ended March 31, 2008.

Net sales of Chem Rx Corporation for the first quarter ended March 31, 2008 were $87.5 million, a 20.2% increase compared to $72.8 million for the first quarter ended March 31, 2007. This growth was primarily attributed to increased beds serviced by the Company's New Jersey, Pennsylvania and New York facilities, principally as a result of continued focus on relationship management and high quality of service.

Adjusted earnings before interest, income taxes, depreciation and amortization ("Adjusted EBITDA") was $5.5 million for the first quarter ended March 31, 2008, compared to pro forma Adjusted EBITDA of $5.7 million for the first quarter ended March 31, 2007. Adjusted EBITDA is a non-GAAP financial measure.

Gross profit for the first quarter ended March 31, 2008 was $22.0 million, a 21.5% increase compared to pro forma gross profit of $18.1 million for the quarter ended March 31, 2007. Gross profit as a percentage of net sales was 25.1% and 24.8% for the three months ended March 31, 2008 and 2007, respectively. The increase in the gross profit dollars and percent was attributable to the growth in net sales, coupled with efficiencies resulting from greater utilization of the Company's facilities and other fixed-cost resources.

Selling, general and
'/>"/>

SOURCE Chem Rx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Genaera Corporations 2008 Annual Stockholder Meeting Results
2. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
3. AMERIGROUP Corporation to Present at the Goldman Sachs 29th Annual Global Healthcare Conference on June 11
4. CuraGen Corporation Regains NASDAQ Listing Compliance
5. Kewaunee Scientific Corporation Increases Quarterly Dividend
6. Alsius Corporation Awarded Three-Year Agreement With Premier, Inc.
7. Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders
8. GenoLogics Releases BioVault Biospecimen Management Software in Partnership With GenVault Corporation
9. Linkwell Corporation Runs 24/7 Disinfectant Operations to Support Chinas Earthquake Relief Efforts
10. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
11. Alsius Corporation Awarded Three-Year Agreement with HealthTrust Purchasing Group
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Delinquent boys at increased risk of premature death and disability by middle age 2Health News:Delinquent boys at increased risk of premature death and disability by middle age 3Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 3Health News:Kroll Fraud Solutions to Host Webinar for Healthcare Organizations on Achieving HITECH Compliance 2Health News:Kroll Fraud Solutions to Host Webinar for Healthcare Organizations on Achieving HITECH Compliance 3Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3New Research Shows a Vitamin/Nutriceutical Formulation Improves Memory and Cognitive Performance in Community-Dwelling Adults 2Critical Alerts for CVX DOW AA ISRG and CELG Released by Seven Summits Research 47774 1Critical Alerts for CVX DOW AA ISRG and CELG Released by Seven Summits Research 47774 2Critical Alerts for CVX DOW AA ISRG and CELG Released by Seven Summits Research 47774 3Visage Imaging to Provide Visage 28R 29 CS Enterprise Wide Advanced Visualization Solutions to Advanced Radiology Consultants 12444 1Visage Imaging to Provide Visage 28R 29 CS Enterprise Wide Advanced Visualization Solutions to Advanced Radiology Consultants 12444 25 Spanish centers join a study for a new leukemia and lymphoma treatment technique 47772 15 Spanish centers join a study for a new leukemia and lymphoma treatment technique 47772 2